201 related articles for article (PubMed ID: 26653553)
1. Expression of c-erb-B2 gene in bladder cancer of Egyptian patients and its correlation with p53 and bcl-2.
Sakr SA; Mahran HA; Fahmy AM; El-Kholy MA; Meawad M
Biomed Pharmacother; 2015 Dec; 76():73-81. PubMed ID: 26653553
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of amplification of c-erb-B2 in bladder carcinoma.
Lönn U; Lönn S; Friberg S; Nilsson B; Silfverswärd C; Stenkvist B
Clin Cancer Res; 1995 Oct; 1(10):1189-94. PubMed ID: 9815911
[TBL] [Abstract][Full Text] [Related]
3. Expression of bcl-2 and bcl-X in bladder cancer.
Kirsh EJ; Baunoch DA; Stadler WM
J Urol; 1998 Apr; 159(4):1348-53. PubMed ID: 9507882
[TBL] [Abstract][Full Text] [Related]
4. Detection of C-erb B2 gene amplification in bilharzial associated bladder cancer using fluorescence in situ hybridization.
Aly MS; Khaled HM
Urol Oncol; 2004; 22(6):448-52. PubMed ID: 15610859
[TBL] [Abstract][Full Text] [Related]
5. p53 and bcl-2 overexpression as associated risk factors in patients 40 years old or less with transitional cell carcinoma of the bladder.
Asci R; Yildiz L; Sarikaya S; Buyukalpelli R; Yilmaz AF; Kandemir B
Urol Int; 2001; 67(1):34-40. PubMed ID: 11464113
[TBL] [Abstract][Full Text] [Related]
6. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
7. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C
Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
[TBL] [Abstract][Full Text] [Related]
8. Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients.
Gorgoulis VG; Barbatis C; Poulias I; Karameris AM
Mod Pathol; 1995 Sep; 8(7):758-64. PubMed ID: 8539234
[TBL] [Abstract][Full Text] [Related]
9. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder.
Coogan CL; Estrada CR; Kapur S; Bloom KJ
Urology; 2004 Apr; 63(4):786-90. PubMed ID: 15072912
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the p53 gene in schistosomal bladder cancer: a study of 92 tumours from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumours.
Warren W; Biggs PJ; el-Baz M; Ghoneim MA; Stratton MR; Venitt S
Carcinogenesis; 1995 May; 16(5):1181-9. PubMed ID: 7767983
[TBL] [Abstract][Full Text] [Related]
11. C-erb-2 gene amplification and chromosomal anomalies in bladder cancer: preliminary results.
Leonardo C; Merola R; Orlandi G; Leonardo F; Rondoni M; De Nunzio C
J Exp Clin Cancer Res; 2005 Dec; 24(4):633-8. PubMed ID: 16471327
[TBL] [Abstract][Full Text] [Related]
12. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder.
Shiina H; Igawa M; Urakami S; Honda S; Shirakawa H; Ishibe T
J Clin Pathol; 1996 May; 49(5):395-9. PubMed ID: 8707954
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder.
Uchida T; Minei S; Gao JP; Wang C; Satoh T; Baba S
Oncol Rep; 2002; 9(2):253-9. PubMed ID: 11836589
[TBL] [Abstract][Full Text] [Related]
15. Use of immunohistochemically demonstrated c-erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder.
Lipponen P; Eskelinen M; Syrjänen S; Tervahauta A; Syrjänen K
Eur Urol; 1991; 20(3):238-42. PubMed ID: 1688050
[TBL] [Abstract][Full Text] [Related]
16. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
[TBL] [Abstract][Full Text] [Related]
17. Absence of frameshift mutations in the bax gene in renal cell cancer (RCC) and transitional cell cancer (TCC).
Bilim VN; Kawasaki T; Takahashi K; Tomita Y
Anticancer Res; 1998; 18(3A):1655-9. PubMed ID: 9673385
[TBL] [Abstract][Full Text] [Related]
18. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2.
Vollmer RT; Humphrey PA; Swanson PE; Wick MR; Hudson ML
Cancer; 1998 Feb; 82(4):715-23. PubMed ID: 9477105
[TBL] [Abstract][Full Text] [Related]
19. Urinary bladder transitional cell carcinogenesis is associated with down-regulation of NF1 tumor suppressor gene in vivo and in vitro.
Aaltonen V; Boström PJ; Söderström KO; Hirvonen O; Tuukkanen J; Nurmi M; Laato M; Peltonen J
Am J Pathol; 1999 Mar; 154(3):755-65. PubMed ID: 10079253
[TBL] [Abstract][Full Text] [Related]
20. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]